Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 451 to 500 of 903

TitleReference numberPublishedLast updated
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapyTA692
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemiaTA694
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myelomaTA695
Avelumab for treating metastatic Merkel cell carcinomaTA517
Acalabrutinib for treating chronic lymphocytic leukaemiaTA689
Avelumab for untreated metastatic Merkel cell carcinomaTA691
Anakinra for treating Still's diseaseTA685
Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)TA686
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA687
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic diseaseTA684
Erenumab for preventing migraineTA682
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancerTA683
Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myelomaTA680
Baricitinib for treating moderate to severe atopic dermatitisTA681
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphomaTA677
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)TA678
Dapagliflozin for treating chronic heart failure with reduced ejection fractionTA679
Filgotinib for treating moderate to severe rheumatoid arthritisTA676
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)TA674
Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal)TA675
Trabectedin for the treatment of advanced soft tissue sarcomaTA185
Mepolizumab for treating severe eosinophilic asthmaTA671
Brolucizumab for treating wet age-related macular degenerationTA672
Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitorTA670
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancerTA668
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinomaTA666
Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpuraTA667
Liraglutide for managing overweight and obesityTA664
Upadacitinib for treating severe rheumatoid arthritisTA665
Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancerTA660
Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinomaTA661
Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal)TA662
Siponimod for treating secondary progressive multiple sclerosisTA656
Drug-eluting stents for the treatment of coronary artery diseaseTA152
Guidance on the use of coronary artery stentsTA71
Carfilzomib for previously treated multiple myelomaTA657
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myelomaTA658
Galcanezumab for preventing migraineTA659
Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapyTA655
Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancerTA653
Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancerTA654
Pembrolizumab with axitinib for untreated advanced renal cell carcinomaTA650
Naldemedine for treating opioid-induced constipationTA651
Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphomaTA649
Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal)TA647
Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal)TA646
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphomaTA641
Gilteritinib for treating relapsed or refractory acute myeloid leukaemiaTA642
Entrectinib for treating ROS1-positive advanced non-small-cell lung cancerTA643
Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplantTA640

Results per page

  1. 10
  2. 25
  3. 50
  4. All